Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 935-847-3 | CAS number: 1369773-39-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Nov 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Single dose acute toxicity testing for pharmaceuticals: Revised guideline. Federal Register, August 26. 1998. p 43934-43935
- Version / remarks:
- Chengelis 1995
- GLP compliance:
- yes
- Test type:
- acute toxic class method
Test material
- Reference substance name:
- calcium bis(3-{[(2S,4R)-1-{[1,1'-biphenyl]-4-yl}-5-ethoxy-4-methyl-5-oxopentan-2-yl]carbamoyl}propanoate)
- EC Number:
- 935-847-3
- Cas Number:
- 1369773-39-6
- Molecular formula:
- C48H56CaN2O10
- IUPAC Name:
- calcium bis(3-{[(2S,4R)-1-{[1,1'-biphenyl]-4-yl}-5-ethoxy-4-methyl-5-oxopentan-2-yl]carbamoyl}propanoate)
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 3 males and 3 females/ group ( Groups 1 - 4)
5 males and 5 females/group (Group 5)
Room temperature: 18° to 26°C
Room relative humidity: 30 to 70%
Lighting cycle: Artificial light for a 12-hour light/12-hour dark cycle
Animal caging: In stainless steel wire cages in compliance with the NRC
(National Research Council) Guide for the Care and Use of Laboratory Animals.
Diet: Teklad Certified LM-485 Rodent Diet #7012C ad libitum. except approximately 4 hours prior to dose (fast) until approximately 2 hours post-dose.
Analysis of diet: The lot number(s) and specifications of each lot used are archived at Calvert.
Water was provided to the animals ad libitum
Periodic analyses of the water were performed and the results are archived at Calvert.
Animals were housed individually and in compliance with the National Research Council
"Guide for the Care and Use of Laboratory Animals". Temperature and relative humidity
were monitored daily. Calvert is USDA registered and a fully accredited AAALAC facility.
There were no known contaminants in the diet or water which, at the levels detected.
interfered with the purpose, conduct or outcome of the study.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 0.5% (w/v) sodium carboxymethylcellulose [CMC] (high viscosity 1500-3000 cps)
- Details on oral exposure:
- Route and frequency: Oral, once to each rat
Dose volume: 20 mL/kg
AI-IU377 in 0.5% (w/v) sodium carboxymethylcellulose (0.5% CMC). The actual dose preparation procedures were documented in the raw data and presented as follows:
The amount of AHU3 77 required for each batch was based on the batch size.
Dosing formulations were prepared by gradual addition of 0.5% CMC to the calculated amount of test article, using a mortar and pestle. The suspensions were transferred to an appropriate HPDE container and the mortar and pestle were rinsed with vehicle. A stir bar was added and the mixture was thoroughly mixed for over an hour. The contents were then transferred to a graduated cylinder and the remaining vehicle was added. The formulations were then transferred
back into the HOPE container. The following preparations reflect the total amounts used to make each final dosing formulation. - Doses:
- Five groups consisting of five animals per sex per group were allocated to the study. Four groups consisting of three animals per sex per group were dosed at 0. 50. 250 and 1000 mg/kg on Day I. Since neither lethality nor other relevant clinical signs were observed. the remaining two animals per sex of Groups 1 thru 4 were not dosed and all animals allocated to Group 5 (5/sex) were dosed at 2000 mg/kg.
- No. of animals per sex per dose:
- Five groups consisting of five animals per sex per group were allocated to the study. Four groups consisting of three animals per sex per group were dosed at 0. 50. 250 and 1000 mg/kg on Day I. Since neither lethality nor other relevant clinical signs were observed. the remaining two animals per sex of Groups 1 thru 4 were not dosed and all animals allocated to Group 5 (5/sex) were dosed at 2000 mg/kg.
- Control animals:
- yes
- Details on study design:
- Pretest period: A minimum of at least 5 days was allowed between animal receipt and the start of dosing to acclimate animals to the laboratory environment and to observe them for the development of infectious disease.
Study period: Fifteen days
The test article dosing preparations were administered once to each rat orally. Each animal received 20 mL/kg via a syringe (5 cc) and a 16 g gavage needle. The dosing formulations were shaken then stirred via a magnetic stir plate and stir bar prior to dosing and continued during dosing. Unused portions of dosing formulations were discarded at the end of each dosing day.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- There was no mortality
- Clinical signs:
- other: No clinical signs were observed in any animals receiving the vehicle formulation or the test article at 50, 250, 1000 and 2000 mg/kg during the study with the exception of soft feces in one animal at the 6 hour observation at the 2000 mg/kg dose level.
- Gross pathology:
- There were no gross necropsy findings in any of the animals receiving the vehicle formulation
or the test article at 50, 250, 1000 or 2000 mg/kg.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Single oral administration of AHU377 at 50, 250, 1000 and 2000 mg/kg to rats revealed no clinical signs with an absence of mortality. Under the conditions of this study, a no-effect level was identified at 2000 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
